Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial

In this RCT (n=120), non-inferiority was not demonstrated for dose reduction of adalimumab, etanercept, and ustekinumab based on PASI in patients with psoriasis vs. usual care with the chosen noninferiority margin. Dose tapering did not lead to persistent flares or safety issues.


JAMA Dermatology